Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreNo recent work listed

Β. Michael Ghadimi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0767-6009; OpenAlex author ID A5000607231, A5031392514. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: none · 2015: none · 2016: 4 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers

Papers 12

  1. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgac092↗
  2. Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy. Co-author DOI 10.3390/cancers14051301↗
  3. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.1002/ijc.32733↗
  4. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Last author DOI 10.1093/jnci/djv387↗
  5. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  6. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0511↗
  7. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Co-author DOI 10.18632/oncotarget.10323↗
  8. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.27762↗
  9. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗
  10. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-0362↗
  11. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-0209↗
  12. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0031507↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jochen Gaedcke · 12 shared papers, 2012–2022 · strength 0.73
  2. Nader N Hanna · 9 shared papers, 2012–2022 · strength 0.49
  3. S. Perwez Hussain · 9 shared papers, 2012–2022 · strength 0.49
  4. Shouhui Yang · 5 shared papers, 2016–2022 · strength 0.37
  5. H. Richard Alexander · 8 shared papers, 2012–2020 · strength 0.36
  6. Jian Wang · 4 shared papers, 2016–2020 · strength 0.24
  7. Matthias M. Gaida · 4 shared papers, 2016–2020 · strength 0.24
  8. Azadeh Azizian · 2 shared papers, 2020–2022 · strength 0.22
  9. Dong Ho Lee · 3 shared papers, 2012–2020 · strength 0.17
  10. Hannah Flebbe · 1 shared paper, 2022 · strength 0.16
  11. Marian Grade · 1 shared paper, 2022 · strength 0.16
  12. Stefan Rieken · 1 shared paper, 2022 · strength 0.16
  13. Günter Schneider · 1 shared paper, 2022 · strength 0.16
  14. Alexander Otto König · 1 shared paper, 2022 · strength 0.16
  15. Lin Zhang · 1 shared paper, 2022 · strength 0.13
  16. Yuuki Ohara · 1 shared paper, 2022 · strength 0.13
  17. Geng Zhang · 4 shared papers, 2012–2013 · strength 0.12
  18. Naotake Funamizu · 3 shared papers, 2012–2016 · strength 0.10
  19. Jens Werner · 2 shared papers, 2016 · strength 0.09
  20. Limin Wang · 1 shared paper, 2020 · strength 0.09
  21. Anirban Maitra · 3 shared papers, 2012–2013 · strength 0.09
  22. Katsuhiko K. Yanaga · 2 shared papers, 2013–2016 · strength 0.07
  23. Dong Ki Lee · 1 shared paper, 2016 · strength 0.05
  24. Tadashi Uwagawa · 1 shared paper, 2016 · strength 0.05
  25. Thomas P. Hank · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.